Breaking News Instant updates and real-time market news.

AET

Aetna

$194.80

0.28 (0.14%)

, JNJ

Johnson & Johnson

$130.20

-0.55 (-0.42%)

08:52
08/14/18
08/14
08:52
08/14/18
08:52

FDA to hold a meeting

The FDA holds a meeting, " Pediatric Medical Device Development", to identify strategies that enhance the medical device ecosystem toward development and innovation of devices that serve the complex needs of children, and thereby accelerate medical device innovation for all Americans. The meeting will be held at the FDA Silver Spring, MD offices on August 14 at 8:30 am. Webcast Link

AET

Aetna

$194.80

0.28 (0.14%)

JNJ

Johnson & Johnson

$130.20

-0.55 (-0.42%)

KIDS

OrthoPediatrics

$27.74

0.09 (0.33%)

MDT

Medtronic

$90.74

0.14 (0.15%)

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

AET Aetna
$194.80

0.28 (0.14%)

08/09/18
RBCM
08/09/18
NO CHANGE
Target $90
RBCM
Outperform
CVS Health price target raised to $90 from $84 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $90 and kept his Outperform rating after its Q2 results. The analyst notes that the quarter benefited from expense timing, given that its FY18 outlook has been largely maintained. Hill also maintains his positive outlook on the Aetna (AET) transaction and the impact of regulatory changes on the company.
07/20/18
CHLM
07/20/18
NO CHANGE
Target $23
CHLM
Buy
Buy Natera shares on any potential post-Aetna weakness, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak says news that Aetna (AET) updated its prenatal testing medical policy, deciding not to cover average risk testing, is "disappointing" given ACOG's recent stance change on average risk, telling investors he believes Aetna's decision adds risk to UnitedHealth's (UNH) upcoming review, which is scheduled for early 2019. Nowak says he continues to like the Natera (NTRA) story and long-term potential and would be buying shares on any possible post-Aetna weakness.
07/09/18
SBSH
07/09/18
UPGRADE
Target $81
SBSH
Buy
CVS Health assumed to Buy from Neutral at Citi
Citi analyst Ralph Giacobbe upgraded CVS Health (CVS) to Buy after assuming coverage of the name. The analyst raised his price target for the shares to $81 from $68. While the execution of an integrated healthcare superstore post the pending Aetna (AET) acquisition may be a long way off, the concept will resonate with employers and individuals, Giacobbe tells investors in a research note. He believes deal integration and competitive Amazon (AMZN) risk are "somewhat overstated particularly in the context of heavily discounted valuation."
07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Risk adjuster suspension positive for Centene and Molina, says Piper Jaffray
Centers for Medicare & Medicaid Services suspending risk adjusters for the health exchange will likely cost the government and consumers more, but it could be positive for Centene (CNC) and Molina Healthcare (MOH), Piper Jaffray analyst Sarah James tells investors in a research note. Both companies are in a net payable position for 2017 and not having to pay these funds would allow the plans to retain cash, the analyst adds. James also sees a positive read-through for UnitedHealth (UNH), Aetna (AET) and Cigna (CI). The analyst finds it most likely that CMS will seek to adjust the risk adjusters in the end rather than cancel the program, but she adds the agency only has a few weeks for them to sort this out, which she feels is not enough time.
JNJ Johnson & Johnson
$130.20

-0.55 (-0.42%)

07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/13/18
FBCO
07/13/18
NO CHANGE
Target $151
FBCO
Outperform
J&J verdict likely to increase attention on lawsuits, says Credit Suisse
After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
KIDS OrthoPediatrics
$27.74

0.09 (0.33%)

08/09/18
PIPR
08/09/18
NO CHANGE
Target $33
PIPR
Overweight
OrthoPediatrics target raised to $33 on 'excellent' momentum at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for OrthoPediatrics to $33 from $30 saying the company's business momentum is "excellent" following its beat and raise Q2. OrthoPediatrics remains a unique name within orthopedics that investors should own, O'Brien tells investors in a research note. He keeps an Overweight rating on the name.
01/05/18
PIPR
01/05/18
NO CHANGE
Target $24
PIPR
Overweight
Piper says OrthoPediatrics' Q4 pre-announcement shows growth 'clicking along'
Piper Jaffray analyst Matt O'Brien noted that OrthoPediatrics pre-announced Q4 revenue that topped his expectations and the consensus view, which he points to as proof that the company's growth story keeps "clicking along." While acknowledging the company will face tough comps next year, he said he is confident the business will continue to accelerate as the company invests its IPO proceeds. O'Brien reiterates an Overweight rating and $24 price target on OrthoPediatrics shares.
04/05/18
PIPR
04/05/18
NO CHANGE
Target $24
PIPR
Overweight
OrthoPediatrics pullback brings 'excellent' entry point, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says the recent pullback in shares of OrthoPediatrics provides an "excellent" entry point. The stock is down nearly 33% in the past three months despite beating expectations the first two quarters out of the gate as a public company, O'Brien tells investors in a research note. The analyst is unsure why the shares sold off, noting OrthoPediatrics' fundamentals "are quite good" with the company releasing five products in the past twelve months and has another five scheduled during 2018. He keeps an Overweight rating on the shares with a $24 price target.
07/05/18
PIPR
07/05/18
NO CHANGE
Target $30
PIPR
Overweight
OrthoPediatrics price target raised to $30 from $24 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for OrthoPediatrics to $30 after hosting investor meetings with management. Operating in a "relatively niche but sizeable" $1.1B domestic market has allowed OrthoPediatrics to "fly under the radar as competitors have overlooked the many unmet medical needs in the space," O'Brien tells investors in a research note. He believes the company's key growth driver is deploying new instrument sets and notes it has already deployed $5.5M out of $10M in new sets this year. The analyst sees "many catalysts" for OrthoPediatrics and reiterates an Overweight rating on the shares.
MDT Medtronic
$90.74

0.14 (0.15%)

08/13/18
NEED
08/13/18
UPGRADE
Target $119
NEED
Strong Buy
Medtronic upgraded to Strong Buy with $119 price target at Needham
Needham analyst Mike Matson upgraded Medtronic to Strong Buy from Buy and raised his price target for the shares to $119 from $103. The company's product cycle remains robust and it has a number of major products in its pipeline, Matson tells investors in a research note. The analyst sees potential to upside to consensus in fiscal 2019 and finds the stock's current valuation as attractive. Further, Matson believes the new long-term financial targets given at Medtronic's investor day in June "seem more realistic."
08/13/18
NEED
08/13/18
NO CHANGE
Target $150
NEED
Buy
Needham downgrades Zimmer to Buy, upgrades Medtronic to Strong Buy
Needham analyst Micheal Matson downgraded Zimmer Biomet (ZBH) to Buy from Strong with a price target of $150. The analyst also upgraded Medtronic (MDT) to Strong Buy from Buy and raised his price target for the shares to $119 from $103. On Zimmer, the analyst cites lower growth potential and valuation for taking his rating to Buy. For Medtronic, Matson expects a strong product cycle and sees potential upside to consensus estimates.
08/13/18
NEED
08/13/18
UPGRADE
NEED
Strong Buy
Medtronic upgraded to Strong Buy from Buy at Needham
08/10/18
RHCO
08/10/18
NO CHANGE
Target $170
RHCO
Buy
Edwards Lifesciences price target lowered to $170 from $180 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Edwards Lifesciences to $170 citing increased Transcatheter aortic valve replacement, or TAVR, competition. The analyst keeps his Buy rating on the shareshowever, expecting the company to show increased TAVR momentum in the U.S. in Q4 thanks to the "Partner 3 CAP program and the Centera U.S. IDE which will likely cannibalize CoreValve".

TODAY'S FREE FLY STORIES

SYF

Synchrony

$24.77

0.38 (1.56%)

11:53
12/12/18
12/12
11:53
12/12/18
11:53
Conference/Events
Synchrony management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LOW

Lowe's

$88.36

-1.13 (-1.26%)

11:53
12/12/18
12/12
11:53
12/12/18
11:53
Technical Analysis
Technical Take: Lowe's spikes after trading halt comes off »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

CASY

Casey's General Stores

$131.98

2.48 (1.92%)

11:52
12/12/18
12/12
11:52
12/12/18
11:52
Recommendations
Casey's General Stores analyst commentary  »

Casey's General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UXIN

Uxin

$7.91

2.01 (34.07%)

, BABA

Alibaba

$154.96

3.13 (2.06%)

11:49
12/12/18
12/12
11:49
12/12/18
11:49
Hot Stocks
China used car platform Uxin spikes over 30% after Taobao's Shopping Festival »

Uxin Limited (UXIN)…

UXIN

Uxin

$7.91

2.01 (34.07%)

BABA

Alibaba

$154.96

3.13 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$88.36

-1.13 (-1.26%)

11:48
12/12/18
12/12
11:48
12/12/18
11:48
Hot Stocks
Breaking Hot Stocks news story on Lowe's »

Lowe's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

LOW

Lowe's

$88.36

-1.13 (-1.26%)

, HD

Home Depot

$174.91

2.66 (1.54%)

11:48
12/12/18
12/12
11:48
12/12/18
11:48
Technical Analysis
Technical Take: Home Depot spikes after Lowe's reiterates guidance, buybacks »

Shares of Home Depot (HD)…

LOW

Lowe's

$88.36

-1.13 (-1.26%)

HD

Home Depot

$174.91

2.66 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

NOW

ServiceNow

$190.56

7.18 (3.92%)

11:47
12/12/18
12/12
11:47
12/12/18
11:47
Conference/Events
ServiceNow management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

JNJ

Johnson & Johnson

$147.43

0.91 (0.62%)

11:45
12/12/18
12/12
11:45
12/12/18
11:45
Conference/Events
Johnson & Johnson management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

VVV

Valvoline

$20.61

0.15 (0.73%)

11:45
12/12/18
12/12
11:45
12/12/18
11:45
Conference/Events
Valvoline management to meet with Wolfe Research »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PKD

Parker Drilling

$1.12

(0.00%)

11:39
12/12/18
12/12
11:39
12/12/18
11:39
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Parker Drilling trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$146.29

4.22 (2.97%)

11:37
12/12/18
12/12
11:37
12/12/18
11:37
Periodicals
Facebook and ZeniMax settle VR copyright lawsuit, Engadget says »

Facebook and ZeniMax have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$88.18

-1.31 (-1.46%)

11:36
12/12/18
12/12
11:36
12/12/18
11:36
Earnings
Lowe's sees FY19 EPS $6.00-$6.10, consensus $5.91 »

Sees FY19 total sales up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

LOW

Lowe's

$88.16

-1.33 (-1.49%)

11:35
12/12/18
12/12
11:35
12/12/18
11:35
Earnings
Lowe's Lowe's sees FY18 adj. EPS $5.08-$5.13, consensus $5.11 »

Sees FY18 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

LOW

Lowe's

$88.42

-1.07 (-1.20%)

11:34
12/12/18
12/12
11:34
12/12/18
11:34
Hot Stocks
Breaking Hot Stocks news story on Lowe's »

Lowe's reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

LOW

Lowe's

$88.42

-1.07 (-1.20%)

11:34
12/12/18
12/12
11:34
12/12/18
11:34
Hot Stocks
Lowe's announces new $10B share repurchase program »

Underscoring its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

RIG

Transocean

$8.47

0.395 (4.89%)

11:31
12/12/18
12/12
11:31
12/12/18
11:31
Hot Stocks
Breaking Hot Stocks news story on Transocean »

Asia Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$37.67

1.08 (2.95%)

11:30
12/12/18
12/12
11:30
12/12/18
11:30
Options
Aggressive call buys in AIG »

Aggressive call buys in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$15.47

-0.03 (-0.19%)

11:29
12/12/18
12/12
11:29
12/12/18
11:29
Recommendations
Intra-Cellular analyst commentary  »

Intra-Cellular price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Sep

JCOM

j2 Global

$70.35

1.09 (1.57%)

11:27
12/12/18
12/12
11:27
12/12/18
11:27
Hot Stocks
j2 Global mentioned cautiously in new GlassHouse Research short report »

GlassHouse Research has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

LOW

Lowe's

$88.53

-0.96 (-1.07%)

11:27
12/12/18
12/12
11:27
12/12/18
11:27
Hot Stocks
Breaking Hot Stocks news story on Lowe's »

Lowe's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 27

    Feb

11:25
12/12/18
12/12
11:25
12/12/18
11:25
Conference/Events
Stephens retail/hardlines analyst to hold luncheon meeting »

Retail Hardlines Analyst…

AVYA

Avaya

$17.78

0.305 (1.75%)

11:24
12/12/18
12/12
11:24
12/12/18
11:24
Hot Stocks
Avaya targets long-term non-GAAP revenue growth CAGR of 2%-4% »

Among other long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

AVYA

Avaya

$17.78

0.305 (1.75%)

11:22
12/12/18
12/12
11:22
12/12/18
11:22
Earnings
Avaya sees FY19 non-GAAP revenue $3.05B-$3.15B, consensus $3.09B »

Sees FY19 non-GAAP gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

TME

Tencent Music

$0.00

(0.00%)

11:20
12/12/18
12/12
11:20
12/12/18
11:20
Syndicate
Breaking Syndicate news story on Tencent Music »

Tencent Music opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AVYA

Avaya

$17.78

0.305 (1.75%)

11:18
12/12/18
12/12
11:18
12/12/18
11:18
Hot Stocks
Breaking Hot Stocks news story on Avaya »

Avaya Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.